FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...

If you experience persistent muscle weakness, fatigue and skin changes that don't seem to fade, it could be more than just ...

Several known risk factors of Dermatomyositis (DM ... She is recognized for her contributions to advancing treatment options and understanding of these challenging conditions.

The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...

Charles Schwab Investment Management Inc. lifted its holdings in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 6.4% in ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...